Microwave-assisted Green Synthesis and Integrated Bioinformatics Study Reveal Curcumin Analogs Dibenzylidene-cyclohexanones as Novel Potential Anti-Tuberculosis Agents
Open Access
- 23 February 2026
- journal article
- Published by Bentham Science Publishers Ltd. in The Open Medicinal Chemistry Journal
- Vol. 20 (1)
Abstract
Introduction: Tuberculosis (TB) remains a major global health challenge, further complicated by drug resistance and comorbidities. This study investigates curcumin analogues, dibenzylidene-cyclohexanones, as potential multitarget anti-TB agents. Methods: Nine benzylidene cyclohexanone derivatives were synthesized using microwave-assisted techniques (yields: 23–81%). Their potential activities were evaluated through molecular docking against key Mycobacterium tuberculosis (Mtb) enzymes and supported by network pharmacology analysis focused on TB-related pathologies. Results: The benzylidene cyclohexanone analogs A-135 (81%), A-144 (58%), and A-154 (30%), synthesized efficiently via microwave-assisted green chemistry, exhibited superior multitarget binding affinities against key Mtb enzymes—A-135 (MtFabH, pantothenate synthetase), A-144 (MurE, DprE1, PTPs), and A-154 (Ddn, GlmU, Pks13)—with halogen substituents enhancing interactions through halogen bonds and lipophilicity; network pharmacology further revealed 294 overlapping TB-related targets and identified NF-κB1, STAT3, STAT1, and PTGS2 as key hubs mediating their multitarget therapeutic potential modulating TB clinical manifestation in human body. Discussion: They exhibited superior multitarget binding affinities against key Mtb enzymes, A-135 (MtFabH, pantothenate synthetase), A-144 (MurE, DprE1, PTPs), and A-154 (Ddn, GlmU, Pks13)—with halogen substituents enhancing interactions through halogen bonds and lipophilicity; network pharmacology further revealed 294 overlapping TB-related targets and identified NF-κB1, STAT3, STAT1, and PTGS2 as key hubs mediating their multitarget therapeutic potential, modulating TB clinical manifestation in the human body. Conclusion: A-135, A-144, and A-154 demonstrate promising multitarget anti-TB activity and potential as adjuvant therapies to complement existing treatments, especially for managing drug resistance and related comorbidities.Keywords
This publication has 54 references indexed in Scilit:
- Recent updates on clinical developments of curcumin and its derivativesPhytotherapy Research, 2023
- Mycobacterium tuberculosis and its secreted tyrosine phosphatasesBiochimie, 2023
- Bioinformatics and network-based approaches for determining pathways, signature molecules, and drug substances connected to genetic basis of schizophrenia etiologyBrain Research, 2022
- Advances in adjunct therapy against tuberculosis: Deciphering the emerging role of phytochemicalsMedcomm, 2021
- Microwave-induced synthesis as a part of green chemistry approach for novel antiinflammatory agents2020
- Molecular Docking Studies in Multitarget Antitubercular Drug Discovery2018
- The Gene Ontology and the Meaning of Biological Function2016
- Synthesis and evaluation of antitubercular activity of fluorinated 5-aryl-4-(hetero)aryl substituted pyrimidinesBioorganic & Medicinal Chemistry, 2016
- The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence AnalysesCurrent Protocols in Bioinformatics, 2016
- Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseasesThe International Journal of Biochemistry & Cell Biology, 2009